Table 1.
Patient characteristics of the IHC cohort.
| Variables N = 460 | Surgery n (%) | CD103 median (range) | (chemo-) RT n (%) | CD103 median (range) | Total n (%) | CD103 median (range) |
|---|---|---|---|---|---|---|
| Patients | 123 (26.7) | 55 (1–367) | 337 (73.3) | 24 (0–256)**** | 460 (100) | 29 (0–367) |
| Age at diagnosis (in years) | ||||||
| Median | 41.2 | 50.7 | 47.7 | |||
| Range | (24.4–84.7) | (20.6–92.0) | (20.6–92.0) | |||
| FIGO stage | ||||||
| IA2 | 0 (0) | 0 (0) | 0 (0) | |||
| IB1 | 86 (69.9) | 52 (1–367) | 77 (22.8) | 38 (0–256) | 163 (35.4) | 50 (0–367) |
| IB2 | 20 (16.3) | 83 (7–286) | 50 (14.8) | 23 (2–204) | 70 (15.2) | 31 (2–286) |
| IIA | 17 (13.8) | 80 (10–203) | 60 (17.8) | 23 (0–215) | 77 (16.7) | 29 (0–215) |
| IIB | 0 (0) | 112 (33.2) | 20 (1–150) | 121 (24.3) | 20 (1–150) | |
| IIIA | 0 (0) | 4 (1.2) | 16 (5–34) | 4 (0.9) | 16 (5–34) | |
| IIIB | 0 (0) | 28 (8.3) | 11 (0–115) | 28 (6.1) | 11 (0–115) | |
| IVA | 0 (0) | 6 (21.8) | 16 (5–43) | 6 (1.3) | 16 (5–43) | |
| Histology | ||||||
| Squamous cell carcinoma | 79 (64.2) | 82 (7–367) | 266 (78.9) | 25 (1–215) | 345 (75.0) | 30 (1–367) |
| Adenocarcinoma | 22 (17.9) | 53 (6–246) | 44 (13.1) | 13 (0–256) | 66 (14.3) | 16 (0–256) |
| Other | 22 (17.9) | 33 (1–186) | 27 (8.0) | 36 (4–199) | 49 (10.7) | 36 (1–286) |
| Grade of differentiation | ||||||
| Good/moderate | 69 (56.1) | 55 (1–367) | 190 (56.4) | 24 (0–215) | 259 (56.3) | 29 ( 0–367) |
| Poor/undifferentiated | 51 (41.5) | 83 (3–303) | 129 (38.3) | 26 (0–256) | 180 (39.1) | 33 (0–304) |
| Unknown | 3 (2.4) | 52 (6–53) | 18 (5.3) | 14 (3–120) | 21 (4.6) | 16 (3–120) |
| Lymphangioinvasion | ||||||
| No | 74 (60.2) | 56 (5–367) | 173 (51.3) | 22 (0–216) | 247 (53.7) | 28 (3–367) |
| Yes | 49 (39.8) | 55 (1–304) | 105 (31.2) | 35 (2–256) | 154 (33.5) | 38 (1–304) |
| Unknown | 0 (0) | 59 (17.5) | 16 (0–128) | 59 (12.8) | 16 (0–128) | |
| Tumor diameter | ||||||
| 0–4 cm | 97 (78.9) | 52 (1–367) | 118 (35.0) | 36 (0–256) | 215 (46.7) | 40 (0–367) |
| ≥ 4 cm | 26 (21.1) | 86 (6–286) | 203 (60.2) | 18 (0–204) | 229 (49.9) | 22 (0–286) |
| Unknown | 0 (0) | 16 (4.7) | 33 (3–128) | 16 (3.5) | 33 (3–128) | |
| Treatment | ||||||
| WM | 123 (100) | 55 (1–367) | ||||
| WM+ post operative RT | 83 (24.6) | 42 (2–256) | ||||
| WM+ Post operative RCT | 14 (4.2)) | 33 (2–84) | ||||
| Primary RT | 115 (34.1) | 22 (0–198) | ||||
| Primary RCT | 125 (37.1) | 16 (0–133) | ||||
| Follow-up (in years) | ||||||
| Median | 5.62 | 4.81 | 5.12 | |||
| Range | (0.53–16.93) | (0.14–21.31) | (0.14–21.31) | |||
| Result last follow-up | ||||||
| No evidence of disease | 109 (88.6) | 77 (3–367) | 168 (49.9) | 29 (0–216) | 227 (60.2) | 38 (0–367) |
| Evidence of disease | 2 (1.6) | 92 (1–184) | 2 (0.6) | 52 (3–102) | 4 (0.9) | 52 (1–184) |
| Death of other disease | 0 (0) | 33 (9.8) | 24 (0–215) | 33 (7.2) | 24 (0–215) | |
| Death of disease | 12 (9.8) | 42 (7–170) | 134 (39.8) | 15 (0–256) | 146 (31.7) | 17 (0–256) |
Abbreviations: FIGO: International Federation of Gynecologists and Obstetricians
WM: Wertheim Meigs RT: Radiotherapy RCT: Radio-chemotherapy